To further explore the role of risk-scores in predicting the therapeutic benefit in the NSCLC disease, the gene profiles of patients who accepted anti-PD-L1 immunotherapy from two GEO datasets were used to calculate risk-scores and assigned into high- and low-risk scores groups. This evidence concerns the gene CD274 and non-small cell lung carcinoma.